Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156651 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL11125768 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1TSHRCYP1A2CYP2D6 | |
| SCHEMBL11105088 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1ABCB1L3MBTL1TSHR | |
| SCHEMBL25434306 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL151213 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL27753904 | 0.82 | CA1 (0.61) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL12129060 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1ABCB1CA12CA1 | |
| SCHEMBL402370 | 0.80 | CA1 (0.62) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| Formaldehyde SCHEMBL28092618 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| Propane SCHEMBL27582651 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPK1ABCB1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| EP-0054132-B1 | PYRIMIDONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-10-10 | — | — | EP | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0054132-A1 | Pyrimidones, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | SMN1; SMN2 3564/4885MAPK1 1831/4885ABCB1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.